The BioPharm Brief: Antibodies, Alliances, and Acquisitions

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's stories all center on one of the industry's busiest areas of innovation, antibody therapeutics. Whether through new drug candidates, strategic collaborations, or acquisitions, companies continue to invest in expanding what's possible with antibody-based medicines.

First, Veraxa Biotech announced that its investigational bispecific antibody-drug conjugate, VXA-222, has reached a key discovery milestone through its collaboration with OmniAb. The candidate combines Veraxa's BiTAC bispecific platform with OmniAb-derived antibodies to target solid tumors. Completion of the discovery phase allows the program to advance into preclinical development, marking another step toward expanding next-generation ADCs designed to improve tumor selectivity and therapeutic precision.

Next, Harbour BioMed and Sinopharm signed an agreement to establish an innovation research and development consortium focused on biologics. The collaboration will span the full development lifecycle, combining Harbour BioMed's antibody discovery technologies and AI-enabled platform with Sinopharm's clinical development and commercialization capabilities. Initially, the consortium will focus on oncology and immune-mediated inflammatory diseases, reflecting continued investment in collaborative biologics development.

Finally, argenx announced plans to acquire Forte Biosciences in a deal valued at approximately $2.2 billion. The acquisition adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline. FB102 is being evaluated across multiple autoimmune diseases, including vitiligo, celiac disease, and alopecia areata, and the acquisition further strengthens argenx's strategy of building a diversified portfolio of immune-targeted therapies.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

• A bispecific ADC candidate moved into the next stage of development following a discovery milestone.
• A new consortium aims to accelerate biologics innovation through antibody discovery and strategic collaboration.
• A $2.2 billion acquisition underscores continued investment in novel antibody therapies for autoimmune disease.